Proteomic Analysis of Small Extracellular Vesicles Uncovers Ongoing Inflammatory and Coagulation Abnormalities in Long-COVID
-
By
-
Sivasankar Chandran
-
Ling Chen
-
Anil Kumar Ram
-
Leslie Spikes
-
Prabhakar Chalise
-
Navneet K. Dhillon
-
July 20, 2026
Clinical Scorecard: Proteomic Analysis of Small Extracellular Vesicles Uncovers Ongoing Inflammatory and Coagulation Abnormalities in Long-COVID
At a Glance
| Category | Detail |
|---|
| Condition | Long-COVID (Post-Acute Sequelae of SARS-CoV-2) |
| Key Mechanisms | Inflammation, coagulation abnormalities, immune dysregulation |
| Target Population | Individuals with persistent symptoms post-COVID-19 infection |
| Care Setting | Clinical research and biomarker identification |
Key Highlights
- 269 dysregulated proteins identified in PASC-positive patients
- Common symptoms include fatigue, shortness of breath, and brain fog
- SEVs show persistent increases in key proteins like HGF and IL-17RA
- Dysregulated proteins are linked to inflammation and coagulation pathways
- Extracellular vesicles may serve as biomarkers for Long-COVID
Guideline-Based Recommendations
Diagnosis
- Identification of ongoing symptoms persisting beyond 6-9 months post-infection
Management
- Monitoring of inflammatory and coagulation markers in PASC patients
Monitoring & Follow-up
- Utilization of small extracellular vesicles as potential biomarkers
Risks
- Multisystemic effects including pulmonary, neuropsychiatric, and cardiovascular symptoms
Patient & Prescribing Data
Patients with post-acute sequelae of SARS-CoV-2 infection
Focus on managing symptoms and monitoring biomarker levels
Clinical Best Practices
- Regular assessment of symptom persistence in COVID-19 survivors
- Consideration of proteomic analysis for understanding Long-COVID mechanisms
- Integration of extracellular vesicle profiling in clinical evaluations
Related Resources & Content
